The role of IL-17 in psoriasis

Mona MalakoutiChicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA, ;Department of Dermatology Psoriasis and Skin Treatment Center, University of California, San Francisco (UCSF), San Francisco, CA, USA, Correspondence[email protected]

Gabrielle Elena BrownDepartment of Dermatology Psoriasis and Skin Treatment Center, University of California, San Francisco (UCSF), San Francisco, CA, USA, ;College of Medicine, University of Arizona, Tucson, AZ, USA, and

Eva WangDepartment of Dermatology Psoriasis and Skin Treatment Center, University of California, San Francisco (UCSF), San Francisco, CA, USA, ;School of Medicine, University of South Alabama, Mobile, AL, USA

John KooDepartment of Dermatology Psoriasis and Skin Treatment Center, University of California, San Francisco (UCSF), San Francisco, CA, USA,

Ethan C. LevinDepartment of Dermatology Psoriasis and Skin Treatment Center, University of California, San Francisco (UCSF), San Francisco, CA, USA,

Abstract

Background: Psoriasis is a chronic skin condition traditionally believed to involve the Th1 pathway. Recently, the IL-23/Th17/IL-17 pathway has been highlighted in the pathogenesis of psoriasis and other autoimmune inflammatory conditions. From a clinician’s perspective, we sought to review the basic science data relevant to IL-17’s role in psoriasis pathogenesis.

Methods: We performed a Pubmed and Web of Knowledge search for English articles starting from 1990 that discussed the Th17 pathway. Search terms such as “IL-17” and “psoriasis” were utilized.

Results: The IL-17 pathway is regulated by IL-23, a cytokine that is vital for the expansion and maintenance of the Th17 cell population. Th17 derived cytokines (IL-17A, IL-17F, IL-17A/F and IL-22) were elevated in both psoriasis-like murine models and human psoriatic lesional biopsies. Ixekizumab (anti-IL-17A) treatment of psoriasis was found to normalize levels of IL-17 downstream gene products.

Conclusion: Both preclinical and clinical studies support the central role of IL-17 in the pathogenesis of psoriasis.

Keywords

Declaration of interest

Dr John Koo is a speaker for AbbVie and Leo. Dr Koo conducts research for Amgen, Janssen, Novartis, Photomedex, Galderma, Pfizer, and Merck. Dr Koo has no stocks, employment or board memberships with any pharmaceutical company. None of the grants were directly related to this article. The other authors (Mona Malakouti, Gabrielle Brown, Eva Wang and Ethan Levin) report no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The role of IL-17 in psoriasis

Information for

Open access

Opportunities

Help and information

The role of IL-17 in psoriasis

Abstract

Declaration of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature